Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: FEBS J. 2021 Feb 11;288(9):2884–2887. doi: 10.1111/febs.15730

Figure 1. Efficacy of PARP inhibitor combined with EZH2 inhibitor may depend on BRCA1/2 mutation status in breast cancer patients.

Figure 1.

Using breast cancer cell lines in xenograft mouse models, studies showed that the tumor response to the PARP inhibitor and EZH2 inhibitor combination varies between models with differing BRCA1 and BRCA2 mutation status.